JPWO2022173670A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022173670A5
JPWO2022173670A5 JP2023547766A JP2023547766A JPWO2022173670A5 JP WO2022173670 A5 JPWO2022173670 A5 JP WO2022173670A5 JP 2023547766 A JP2023547766 A JP 2023547766A JP 2023547766 A JP2023547766 A JP 2023547766A JP WO2022173670 A5 JPWO2022173670 A5 JP WO2022173670A5
Authority
JP
Japan
Prior art keywords
seq
nos
amino acid
set forth
lcdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506315A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015341 external-priority patent/WO2022173670A1/en
Publication of JP2024506315A publication Critical patent/JP2024506315A/ja
Publication of JPWO2022173670A5 publication Critical patent/JPWO2022173670A5/ja
Pending legal-status Critical Current

Links

JP2023547766A 2021-02-09 2022-02-04 コロナウイルスのスパイクタンパク質を標的とする抗体 Pending JP2024506315A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147419P 2021-02-09 2021-02-09
US63/147,419 2021-02-09
PCT/US2022/015341 WO2022173670A1 (en) 2021-02-09 2022-02-04 Antibodies targeting the spike protein of coronaviruses

Publications (2)

Publication Number Publication Date
JP2024506315A JP2024506315A (ja) 2024-02-13
JPWO2022173670A5 true JPWO2022173670A5 (enrdf_load_stackoverflow) 2025-02-06

Family

ID=80447839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547766A Pending JP2024506315A (ja) 2021-02-09 2022-02-04 コロナウイルスのスパイクタンパク質を標的とする抗体

Country Status (11)

Country Link
US (1) US20240117011A1 (enrdf_load_stackoverflow)
EP (1) EP4291226A1 (enrdf_load_stackoverflow)
JP (1) JP2024506315A (enrdf_load_stackoverflow)
KR (1) KR20230142790A (enrdf_load_stackoverflow)
CN (1) CN117642178A (enrdf_load_stackoverflow)
AU (1) AU2022221297A1 (enrdf_load_stackoverflow)
CA (1) CA3209136A1 (enrdf_load_stackoverflow)
CL (1) CL2023002326A1 (enrdf_load_stackoverflow)
IL (1) IL304955A (enrdf_load_stackoverflow)
MX (1) MX2023009244A (enrdf_load_stackoverflow)
WO (1) WO2022173670A1 (enrdf_load_stackoverflow)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065039T2 (hu) 2020-03-26 2024-04-28 Univ Vanderbilt Emberi monoklonális ellenanyagok súlyos akut légzõszervi szindrómát okozó koronavírus 2 (SARS-COV-2) ellen
WO2024040187A2 (en) * 2022-08-19 2024-02-22 The Regents Of The University Of California Sars-cov2 neutralizing single domain antibody constructs
EP4335870A1 (en) * 2022-09-06 2024-03-13 NantCell, Inc. Peptide therapeutics against sars-cov-2 spike protein
WO2024054822A1 (en) * 2022-09-07 2024-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineered sars-cov-2 antibodies with increased neutralization breadth
KR20240072325A (ko) * 2022-11-11 2024-05-24 연세대학교 산학협력단 SARS-CoV-1 검출용 항체 및 이를 이용한 면역친화성 바이오 센서
WO2024124241A2 (en) * 2022-12-09 2024-06-13 Abwiz Bio, Inc. Antibodies or fragments thereof for sars-cov-2 and variants thereof
CN120129695A (zh) * 2022-12-20 2025-06-10 北京昌平实验室 新型冠状病毒xbb.1.5及相关变异株广谱中和抗体及应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DE69841273D1 (de) 1997-11-17 2009-12-17 Micromet Ag Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ATE244758T1 (de) 1998-04-21 2003-07-15 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
EP1914244B1 (en) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
IL151872A0 (en) 2000-03-24 2003-04-10 Micromet Ag mRNA AMPLIFICATION
AU2001295503A1 (en) 2000-08-22 2002-03-04 Micromet Ag Composition for the elimination of autoreactive b-cells
ES2620359T3 (es) 2000-10-06 2017-06-28 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
NZ531219A (en) 2001-08-03 2007-07-27 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
AU2003208839A1 (en) 2002-02-13 2003-09-04 Micromet Ag De-immunized (poly)peptide constructs
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
JPWO2003085107A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
WO2003085102A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
WO2003085119A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DK1572744T3 (da) 2002-12-16 2010-09-20 Genentech Inc Immunoglobulinvarianter og deres anvendelser
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CN100509850C (zh) 2003-05-31 2009-07-08 麦克罗梅特股份公司 用于治疗b细胞相关疾病的包含双特异性抗cd3、抗cd19抗体构建体的药物组合物
EP1629013B1 (en) 2003-05-31 2018-01-24 Amgen Research (Munich) GmbH Pharmaceutical composition comprising a bispecific antibody specific for epcam
WO2005035586A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. 融合蛋白質組成物
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
ATE493441T1 (de) 2003-10-16 2011-01-15 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
CN102373214B (zh) 2003-11-05 2014-07-09 罗氏格黎卡特股份公司 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
NZ562093A (en) 2005-04-18 2011-01-28 Micromet Ag Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2006326727A1 (en) 2005-12-16 2007-06-21 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
EP4157455A1 (en) * 2020-05-29 2023-04-05 Universität zu Köln Neutralizing antibodies against sars-related coronavirus

Similar Documents

Publication Publication Date Title
CN115052895B (zh) 抗SIRPα抗体及其用途
JP2020530272A5 (enrdf_load_stackoverflow)
JP2019527553A5 (enrdf_load_stackoverflow)
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2020534830A5 (enrdf_load_stackoverflow)
IL314799A (en) Human monoclonal antibodies that broadly target coronaviruses
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
JP2025067915A5 (enrdf_load_stackoverflow)
JP2024024114A5 (enrdf_load_stackoverflow)
CN106243223B (zh) 抗人pdl1抗体及其用途
JP2020515277A5 (enrdf_load_stackoverflow)
CN109721656B (zh) 靶向rankl的治疗性抗体
IL315960A (en) Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
JPWO2022173670A5 (enrdf_load_stackoverflow)
KR20240031229A (ko) 알파-시누클레인병증 치료용 항체
EP4410840A1 (en) Bispecific antibody and application thereof
JPWO2021133723A5 (enrdf_load_stackoverflow)
JP2020533022A5 (enrdf_load_stackoverflow)
JPWO2019177854A5 (enrdf_load_stackoverflow)
JPWO2021003297A5 (enrdf_load_stackoverflow)
JPWO2021116337A5 (enrdf_load_stackoverflow)
JPWO2022256563A5 (enrdf_load_stackoverflow)
JPWO2022268192A5 (enrdf_load_stackoverflow)
JPWO2020102555A5 (enrdf_load_stackoverflow)
CN112969715A (zh) 一种抗cd47抗原结合蛋白及其应用